ClinicalTrials.gg
CompletedNCT05503901Updated Jul 15, 2024

A Long Term Study of STN1012600 in Subjects With Open Angle Glaucoma or Ocular Hypertension

A Phase 3 interventional study of STN1012600 ophthalmic solution 0.002% and STN1012600 ophthalmic solution 0.002% in Open Angle Glaucoma, Ocular Hypertension, sponsored by Santen Pharmaceutical Co., Ltd.. Completed at 18 sites in Japan. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-07-15.

Sponsored by Santen Pharmaceutical Co., Ltd. · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
131
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 37 studies in Glaucoma, Open-Angle by Santen Pharmaceutical Co., Ltd. — 1 open to participants now, 2 under way, 1 of them phase 3. Glaucoma, Open-Angle · Santen Pharmaceutical Co., Ltd..

Enrollment
21st of 31
131 · median 165
Started
2022
with 2 others
Phase 3
17 of 37
none open now
Registered
34th of 37
by date

Among the 37 studies in Glaucoma, Open-Angle by Santen Pharmaceutical Co., Ltd., this one is the 21st largest by enrollment of the 31 interventional ones that give a count, is one of 3 that started in 2022, is one of 17 in phase 3, and was the 34th registered.

Glaucoma, Open-Angle

924 studies on the registry are indexed under Glaucoma, Open-Angle; 115 are open to participants now.

Browse Glaucoma, Open-Angle studies →

Open to participants now

1 of the 37 studies in Glaucoma, Open-Angle by Santen Pharmaceutical Co., Ltd. is open now, in 8 countries. Recruiting first, the newest first:

By country, each count listing its studies:

Who these studies take

Of the 82 Glaucoma, Open-Angle studies recruiting now, 63 (77%) set no upper age limit and 5 (6%) stop at 75 or younger; 5 take children under 18; 11 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 37 studies in Glaucoma, Open-Angle by Santen Pharmaceutical Co., Ltd., or all of them as a file.
02

Study summary

To evaluate safety and the ocular hypotensive effect of STN1012600 ophthalmic solution 0.002% alone or in combination with Timolol ophthalmic solution 0.5% for 52 weeks in subjects with open angle glaucoma or ocular hypertension.

03

Conditions studied

  • Open Angle Glaucoma, Ocular Hypertension
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • 18 years of age or older.
  • Diagnosis of OAG or OHT in both eyes, or one eye with OAG and the other with OHT.
  • Corrected Visual Acuity of +0.60 logMAR (Decimal visual acuity 0.3) or better in each eye.

Exclusion criteria

Exclusion Criteria:

  • Presence of any active severe external ocular disease, inflammation, or infection of the eye and/or eyelids in either eye.
  • History of severe ocular trauma in either eye.
  • Any condition that prevents clear visualization of the fundus in either eye.
  • Known allergy, or to any components of the study medications or other study related procedures/medications.
  • History of ocular surgery specifically intended to lower IOP in either eye.
  • History of keratorefractive surgery in either eye.
  • Females who are pregnant, nursing, or planning a pregnancy.
  • Subjects with known or suspected drug or alcohol abuse.
  • Participation in other drugs or device clinical trials within 30 days prior to Screening.
  • Any decision by the Investigator to terminate a subject in screening or declare any subject ineligible for any sound medical reason.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
131 participants (actual)

Study arms

  • Experimental
    Group 1: STN1012600 0.002%

    Drug: STN1012600 ophthalmic solution 0.002%

  • Experimental
    Group 2: STN1012600 0.002%

    Drug: STN1012600 ophthalmic solution 0.002%

  • Experimental
    Group 3: STN1012600 0.002% + Timolol 0.5%

    Drug: STN1012600 ophthalmic solution 0.002% and Timolol ophthalmic solution 0.5%

Interventions

  • 1 drop STN1012600 ophthalmic solution 0.002% once daily for 52 weeks

  • 1 drop STN1012600 ophthalmic solution 0.002% once daily for 52 weeks

  • DrugSTN1012600 ophthalmic solution 0.002% and Timolol ophthalmic solution 0.5%

    Drug page: Sepetaprost

    1 drop STN1012600 ophthalmic solution 0.002% once daily for 52 weeks and 1 drop Timolol ophthalmic solution 0.5% twice daily for 52 weeks

06

What researchers measure

Primary outcomes

  1. Change from baseline in mean diurnal intraocular pressure

    Change from baseline in mean diurnal intraocular pressure at each post-baseline visit

    Time frame: 52 weeks

  2. Percent change from baseline in mean diurnal intraocular pressure

    Percent change from baseline in mean diurnal intraocular pressure at each post-baseline visit

    Time frame: 52 weeks

07

Study locations

18 sites
  • Kitanagoya Eye Clinic
    Aichi, Japan
  • Miyake Eye Hospital
    Aichi, Japan
  • Nagasaka Eye Clinic
    Aichi, Japan
  • Eto Eye Clinic
    Fukuoka, Japan
  • Minamoto Eye Clinic
    Hiroshima, Japan
  • Matsumoto Eye Clinic
    Ibaraki, Japan
  • IGO Ophthalmic Clinic
    Kagoshima, Japan
  • Ohguchi Ophthalmic Clinic
    Kanagawa, Japan
  • Smile Eye Clinic
    Kanagawa, Japan
  • Inamoto Eye Clinic
    Osaka, Japan
  • Kubota Eye Clinic
    Osaka, Japan
  • Nishi Eye Hospital
    Osaka, Japan
  • Onoe Eye Clinic
    Osaka, Japan
  • Red Cross Ogawa Hospital
    Saitama, Japan
  • Nakajima Eye Clinic
    Shizuoka, Japan
  • Hashida Eye Clinic
    Tokyo, Japan
  • Seijo Clinic
    Tokyo, Japan
  • Sinzyuku Eye Clinic
    Tokyo, Japan
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Aug 2022 to primary completion in Jan 2024, 17 months.

Of 47 industry-sponsored phase 3 interventional studies under Glaucoma, Open-Angle, half reached primary completion within 26 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 39. This study's 17 months is below that.

Counting every sponsor, half of 49 studies reached it within 26 months; a quarter within 12 and three quarters within 39.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 9, 2022
First posted
Aug 17, 2022
StartActual
Aug 8, 2022
Primary completionActual
Jan 30, 2024
CompletionActual
Jan 30, 2024
Last update
Jul 15, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 15, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05503901
Responsible party
Sponsor
First posted
Aug 17, 2022
Start date
Aug 8, 2022
Primary completion
Jan 30, 2024
Completion
Jan 30, 2024
Last update
Jul 15, 2024

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Sepetaprost

Start the discussion